Trends in the development of chiral drugs

Drug Discovery Today

Volumn 9, Issue 3, 2004, Pages 105-110

  Caner, Hava ^a   Groner, Efrat ^a   Levy, Liron ^a   Agranat, Israel ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Achiral; Chiral Switch; Drug Discovery; NME; Pharmaceutical Science; Pharmacology; Racemate; Regulatory Control; Single Enantiomer; Stereochemistry; Thalidomide

Indexed keywords

AMOXICILLIN; ATORVASTATIN; CLAVULANATE POTASSIUM; CLOPIDOGREL; DEXFENFLURAMINE; DEXMETHYLPHENIDATE; ESCITALOPRAM; ESOMEPRAZOLE; FLUTICASONE PROPIONATE; LEVALBUTEROL; LEVOBUPIVACAINE; LEVOCETIRIZINE; LEVOFLOXACIN; NEW DRUG; PAROXETINE; PRAVASTATIN; SALMETEROL XINAFOATE; SERTRALINE; SIMVASTATIN; THALIDOMIDE; VALSARTAN;

CHIRALITY; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; ENANTIOMER; FOOD AND DRUG ADMINISTRATION; REVIEW; STEREOCHEMISTRY;

EID: 1042302102     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02904-0     Document Type: Short Survey

References (20)

1. Eichelbaum, M., Testa, B. and Somogyi A., eds (2003) Stereochemical Aspects of Drug Action and Disposition, Springer.
2. Eichelbaum M., Gross A.S. Stereochemical aspects of drug action and disposition. Adv. Drug Res. 28:1996;1-64.
3. Caldwell J. Through the looking glass in chiral drug development. Modern Drug Discov. 2:1999;51-60.
4. Agranat I., Caner H., Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat. Rev. Drug Discov. 1:2002;753-768.
5. Shah R.R. Improving clinical risk/benefit through stereochemistry. Eichelbaum M., Testa B., Somogyi A. Stereochemical Aspects of Drug Action and Disposition. 2003;401-432 Springer.
6. FDA's policy statement for the development of new stereoisomeric drugs. 57 Fed. Reg. 22:1992;249.
7. Committee for Proprietary Medical Products (1993) Working parties on quality, safety and efficacy of medical products. Note for guidance: investigation of chiral active substances. III/3501/91.
8. Stinson S.C. Counting on chirality. Chem. Eng. News. 76:(38):1998;83-104.
9. Stinson S.C. Chiral drug interactions. Chem. Eng. News. 77:(41):1999;101-120.
10. Stinson S.C. Chiral drugs. Chem. Eng. News. 78:(43):2000;55-78.
11. Stinson S.C. Chiral pharmaceuticals. Chem. Eng. News. 79:(40):2001;79-97.
12. Rouhi A.M. Chiral roundup. Chem. Eng. News. 80:(23):2002;43-50.
13. Rouhi A.M. Chiral business. Chem. Eng. News. 81:(18):2003;45-55.
14. Shah R.R., Branch S.K. Regulatory requirements for the development of chirally active drugs. Eichelbaum M., et al. Stereochemical Aspects of Drug Action and Disposition. 2003;379-399 Springer.
15. Miller, S.P. (2001) FDA perspective on quality control for chiral pharmaceuticals. 13th International Symposium on Chiral Discrimination (abstract L/316).
16. Bristol, J.A. and Doherty, A.M. eds. (1984-2003) To Market, To Market. In Annual Reports in Medicinal Chemistry, 19-38, Academic Press.
17. Rouhi A.M. Chirality at work. Chem. Eng. News. 81:(18):2003;56-61.
18. Hilts, P.J. (2003) Protecting America's Health: the FDA Business, and One Hundred Years of Regulation. pp. 144-165. Alfred A. Knopf, New York.
19. Agranat I., Caner H. Intellectual property and chirality of drugs. Drug Discov. Today. 4:1999;313-321.
20. Patent watch. A new twist on the chiral switch. Nat. Rev. Drug Discov. 2:2003;424.